

Lipocalin 2 and its receptor, megalin, as diagnostic and drug targets in early stages of Alzheimer's disease.

<https://www.neurodegenerationresearch.eu/survey/lipocalin-2-and-its-receptor-megalin-as-diagnostic-and-drug-targets-in-early-stages-of-alzheimer%c2%92s-disease/>

Name of Fellow

Dr. P.J.W. Naudé

Institution

Funder

ZonMW | Alzheimer Nederland | Neurosearch Antwerp.

Contact information of fellow

Country

The Netherlands

Title of project/programme

Lipocalin 2 and its receptor, megalin, as diagnostic and drug targets in early stages of Alzheimer's disease.

Source of funding information

ZonMW | Alzheimer Nederland | Neurosearch Antwerp.

Total sum awarded (Euro)

€ 150,000

Start date of award

01/11/15

Total duration of award in years

3.0

The project/programme is most relevant to:

Alzheimer's disease & other dementias

Keywords

Neuroinflammation | diagnostic markers | therapeutic target | mild cognitive impairment |

Lipocalin 2 | Megalin | early Alzheimer's disease

Research Abstract

Lipocalin 2 (Lcn2) is a newly identified (neuro)inflammatory component that, together with its receptor, megalin, can play important roles in the pathophysiology of Alzheimer's disease (AD) development. This project will investigate Lcn2 and megalin as novel diagnostic and therapeutic targets for early AD, addressing two fundamental research topics in this field: i.e. early diagnosis and early intervention, aiming to prevent AD development or at least stop or slow down disease progression.

Types:

Fellowships

Member States:

Netherlands

Diseases:

Alzheimer's disease & other dementias

Years:

2016

Database Categories:

N/A

Database Tags:

N/A